What do systematic reviews say?

Self‐management interventions vs usual care

Self‐management interventions showed no clear difference in all‐cause mortality compared with usual care (low certainty).

• Self‐management interventions for people with chronic obstructive pulmonary disease 2022 · Cochrane Headline outcomes only
  OR 0.86 [0.59, 1.26]
  5719 participants
  Low
• Self‐management interventions including action plans for exacerbations versus usual care in patients with chronic… 2017 · Cochrane Headline outcomes only
  OR 1.06 [0.71, 1.59]
  16 studies · 3296 participants
  Moderate

Summary of findings: insulin detemir vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  4.97 [0.79, 31.38]
  9 studies · 3334 participants
  Moderate
• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  Peto OR 0.74 [0.2, 2.65]
  8 studies · 2328 participants
  Low

Insulin glargine vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  0.14 [0, 6.98]
  8 studies · 2175 participants
  Moderate
• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  Peto OR 1.06 [0.62, 1.82]
  14 studies · 6173 participants
  Low

Short‐acting insulin analogues vs regular human insulin

Short‐acting insulin analogues showed no clear difference in all‐cause mortality (N) compared with regular human insulin (moderate certainty).

• Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
  Peto OR 1.66 [0.41, 6.64]
  6 studies · 2519 participants
  Moderate
• Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hydroxyurea vs placebo

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 193 participants
  Low

Intensive glycaemic control vs conventional glucose control

Intensive glycaemic control showed no clear difference in all‐cause mortality compared with conventional glycaemic control (moderate certainty).

• Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus 2013 · Cochrane Headline outcomes only
  RR 1 [0.92, 1.08]
  24 studies · 34325 participants
  Moderate